Furthermore, these pathological effects were dependent on the NLRP3 inflammasome as all were suppressed by NLRP3 knockout, underscoring the therapeutic potential NLRP3 inflammasome blockade for early treatment of AD. Here, NLRP3 is linked to Alzheimer disease.